John Williams Lab
Our research primarily focuses on structural and biophysical methods to identify sources of energy additivity and multivalency in macromolecular complexes and use these properties to develop new tools and novel therapeutics. Based on an ‘atoms-up’ approach, my research team and I have developed chemically-induced molecular traps (Varma, 2010); tumor-activated, masked antibodies (Donaldson, 2009); and monoclonal antibody (mAb) technology called meditopes (Donaldson, 2013, Bzymek 2018, King 2018). One of our most successful efforts to date, the generation of a tumor-activated, anti-CTLA4 mAb, is now in a phase 1/2 clinical trial at Xilio Therapeutics, a company co-founded by Dr. Williams.
Professor, Department of Cancer Biology and Molecular Medicine & Director, X-ray Crystallography Core
Join one of our labs and help us on our mission to save lives.
Kuo YC, Kuo CF, Jenkins K, Hung AF-H, Chang W-C, Park M, Aguila B, Starr B, Hibbard J, Brown C, Williams JC.
King JD, Ma Y, Kuo YC, Bzymek KP, Goodstein LH, Meyer K, Moore RE, Crow D, Colcher DM, Singh G, Horne DA, Williams JC.
Bzymek KP, Puckett JW, Zer C, Xie J, Ma Y, King JD, Goodstein LH, Avery KN, Colcher D, Singh G, Horne DA, Williams JC
Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC.
Buettner R, Corzano R, Rashid R, Lin J, Senthil M, Hedvat M, Schroeder A, Mao A, Herrmann A, Yim J, Li H, Yuan YC, Yakushijin K, Yakushijin F, Vaidehi N, Moore R, Gugiu G, Lee TD, Yip R, Chen Y, Jove R, Horne D, Williams JC.
Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC.
Williams JC, Roulhac PL, Roy AG, Vallee RB, Fitzgerald MC, Hendrickson WA.
Varma D, Dawn A, Ghosh-Roy A, Weil SJ, Ori-McKenney KM, Zhao Y, Keen J, Vallee RB, Williams JC.
Williams JC, Wierenga RK, Saraste M.
- U .S. Patent 11,311,622 “Development of masked therapeutic antibodies to limit off-target effects
- U .S. Patent 11,279,752 “Tumor-selective CTLA-4 antagonists”
- U .S. Patent 11,246,942 “Meditopes and meditope-binding antibodies and uses thereof”
- U.S. Patent 11,186,642 “Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies.”
- U.S. Patent 11,116,834 “Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy”
- U.S. Patent 10,689,423, “CTLA-4binding protein peptide-linker masks”
- U.S. Patent 10,590,205, “Chimeric antigen receptor compositions”
- U.S. Patent 10,414,814, “Tumor-selective CTLA-4 antagonists”
- U.S. Patent 10,357,571, “Development of masked therapeutic antibodies to limit off-target effects”
- U.S. Patent 9,669,108, “Meditopes and meditope-binding antibodies and uses thereof”
- U.S. Patent 9,574,014, “Chimeric antigen receptor compositions”
- U.S. Patent 9,428,553, “Meditopes and meditope-binding antibodies and uses thereof”
- U.S. Patent 9,260,710, “Photocleavable linker”
- U.S. Patent 9,193,791, “Development of masked therapeutic antibodies to limit off-target effects”
- U.S. Patent 9,096,844 “Photocleavable linker”
- U.S. Patent 8,962,804, “Meditopes and meditope-binding antibodies and uses thereof: Delivery Systems, Synthesis and Therapeutic Uses Thereof.”
- U.S. Patent 8,895,702, “Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies.”
- U.S. Patent 8,658,774, “Novel meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof."
34.1293409, -117.971358
Duarte, CA 91010